Project Grant F31CA290730
Award Date
12/1/24
Completion Date
8/31/26
Dollars Obligated
$116K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $671,757 to Virginia Commonwealth University to conduct a randomized controlled trial of a home-based physical activity intervention plus a healthy living intervention, versus the healthy living intervention alone. The goal is to preserve exercise capacity, left ventricular function, and health-related quality of life, and reduce fatigue in 150 women receiving...
This Project Grant award of $414,446 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) will fund a 12-week group-based videoconference intervention to increase moderate to vigorous physical activity (MVPA) among cancer survivors. The study will randomize adult cancer survivors to the intervention or a comparator group, with the intervention including twice-weekly instructor-led aerobic/resistance exercise and PA behavior change sessions...
This $1,290,499 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports a research project led by the Dana-Farber Cancer Institute, Inc. (Dfci) in Boston, MA. The project is studying the effect of clonal hematopoiesis on cardiovascular-related outcomes in patients diagnosed with kidney cancer. The four-year research effort, which commenced on September 1, 2023 and is scheduled for completion by August 31, 2027, aims to advance...
This Project Grant award of $603,803 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support research by the University of Massachusetts Boston to investigate the biomechanical and biomolecular properties of large extracellular vesicles (L-EVs) and their potential as cancer biomarkers. The collaborative project aims to advance microfluidic technology to measure single L-EV characteristics and explore the clinical utility of multiplex L-EV profiling from plasma...
This federal Project Grant award, valued at $746,926 and effective from July 9, 2024 to June 30, 2029, was issued by the National Cancer Institute (CFDA 93.353) under the 21st Century Cures Act - Beau Biden Cancer Moonshot program. The grant funds a multi-site randomized controlled trial to assess the efficacy of a phone-delivered Positive Psychological Intervention (PATH) for improving anxiety, depression, and quality of life in hematopoietic stem cell transplantation (HSCT) survivors. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $623,120 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to research new chemical "degrader" tools that target chromatin regulators critical for the survival and proliferation of multiple myeloma cells. The project aims to investigate the mechanisms of CBP and P300 degradation in myeloma and credential these new chemical tools as candidates...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $130,501 to The Salk Institute for Biological Studies to conduct research on the role of muscle CDKN1A in cancer cachexia. The key objectives are to: 1) elucidate the function of muscle CDKN1A in muscle dysfunction during cancer cachexia, 2) define the temporal regulation of CDKN1A by BCL6 in response to nutrient availability, and 3) assess immune modulation of muscle CDKN1A as a...
This $293,053 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports a 5-year project to refine and pilot test a specialized palliative care intervention (PEACE) for patients with hematologic malignancies receiving adoptive cellular therapy (ACT) and their caregivers. The project aims to 1) refine the PEACE intervention based on findings from an open pilot study, 2) determine the feasibility and acceptability of PEACE through a pilot...
This Cooperative Agreement award, valued at $294,787, was made by the National Cancer Institute (NCI) under the Cancer Treatment Research (CFDA 93.395) program. The award supports the planning and development of a virtual exercise intervention trial aimed at preventing functional decline in cancer patients undergoing chemotherapy. Key components include: Assessing factors associated with functional decline in cancer survivors enrolled in the American Cancer Society Cancer Prevention Study-3...
This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...